As online sales transactions increase in volume year after year, companies that provide tax automation are seeing a major increase in the need for their services. Vertex is one of those companies, and ...

- VX-264 Phase 1/2 enrollment and dosing complete in Parts A and B: VX-264 was generally safe and well tolerated; efficacy data are not supportive of further clinical advancement - - Zimislecel ...

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the company will initiate a Phase 3 development program for the new once-daily investigational triple ...

Vertex Pharmaceuticals is diversifying from its cystic fibrosis dominance into pain, sickle cell disease, beta thalassemia, and type 1 diabetes, with approved products in each area. Suzetrigine ...

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today a new $750,000 program to support the work of young faculty who are newly establishing independent research ...

To receive Vertex and CRISPR Therapeutics’ $2.2 million gene therapy Casgevy for sickle cell disease (SCD) and transfusion dependent beta thalassemia (TDT), patients must first undergo chemotherapy to ...

It had been 11 years since Noah Hoffman ’22 had taken a math class when he arrived on campus this fall. A Resumed Undergraduate Education student and former Olympic cross-country skier, Hoffman ...

KING OF PRUSSIA, Pa., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Vertex, Inc. (NASDAQ: VERX) (“Vertex” or the “Company”), a leading global provider of indirect tax solutions, today announced financial results ...

Vertex Pharmaceuticals is the global leader in cystic fibrosis treatment, and that business generates billions of dollars in annual revenue. The biotech has treatment candidate in another indication ...

The acquisition of Adams marks Vertex’s seventh acquisition under Wind Point ownership Jeff Christmann serves as CEO of Adams The Vertex Companies, a portfolio company of Wind Point Partners, has ...

In a court filing on Monday, the Department of Health and Human Services (HHS) challenged Vertex Pharmaceuticals Inc (NASDAQ:VRTX), defending its stance that the company’s proposed fertility services ...